A Non-Interventional Study (NIS) PASS to characterize secondary malignancies of T-cell origin following tisagenlecleucel therapy (CCTL019B2402) First published 28/01/2026 Last updated 19/02/2026 EU PAS number:EUPAS1000000749 Study Planned